IL33 Is a Stomach Alarmin That Initiates a Skewed Th2 Response to Injury and Infection  by Buzzelli, Jon N. et al.
ORIGINAL RESEARCHIL33 Is a Stomach Alarmin That Initiates a Skewed Th2 Response
to Injury and Infection
Jon N. Buzzelli,1,2 Heather V. Chalinor,1 Daniel I. Pavlic,1 Philip Sutton,1,3
Trevelyan R. Menheniott,1 Andrew S. Giraud,1,2 and Louise M. Judd1,2
1Murdoch Children’s Research Institute, 2Department of Paediatrics, Royal Children’s Hospital, 3Centre for Animal
Biotechnology, School of Veterinary Science, University of Melbourne, Parkville, Victoria, AustraliaAbbreviations used in this paper: AB, Alcian blue; DC, dendritic cell;
ELISA, enzyme-linked immunosorbent assay; ERK, extracellular signal–
regulated kinase; FBS, fetal bovine serum; HBSS, Hank’s balanced salt
solution; IL, interleukin; ILC, innate lymphoid cell; mRNA, messenger
RNA; NF-kB, nuclear factor-kB; PAS, periodic acid–Schiff; PCR, poly-
merase chain reaction; QRT-PCR, quantitative reverse-transcription
polymerase chain reaction; SMC, surface mucus cells; SPF, speciﬁc
pathogen free; SS1, Sydney strain 1; STAT, signal transducer and
activator of transcription; TFF, trefoil factor; Th, T-helper; WT, wild type.
© 2015 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2014.12.003SUMMARY
Interleukin 33 is a stomach alarmin that is increased
immediately after gastric insult and infection but is sup-
pressed during long-term Helicobacter pylori infection.
Interleukin 33 potently activates gastric T helper 2 immu-
nity, which suggests that its loss during H pylori infection
may be important in establishing T helper 1 immunity.
BACKGROUND & AIMS: Interleukin (IL)33 is a recently
described alarmin that is highly expressed in the gastric mu-
cosa and potently activates Th2 immunity. It may play a pivotal
role during Helicobacter pylori infection. Here, we delineate the
role of IL33 in the normal gastric mucosa and in response to
gastropathy.
METHODS: IL33 expression was evaluated in mice and human
biopsy specimens infected with H pylori and in mice after
dosing with aspirin. IL33 expression was localized in the gastric
mucosa using immunoﬂuorescence. Mice were given 1 or 7
daily doses of recombinant IL33 (1 mg/dose), and the stomach
and the spleen responses were quantiﬁed morphologically, by
ﬂow cytometry and using quantitative reverse-transcription
polymerase chain reaction and immunoblotting.
RESULTS: In mice, the IL33 protein was localized to the nu-
cleus of a subpopulation of surface mucus cells, and co-
localized with the surface mucus cell markers Ulex Europaeus
1 (UEA1), and Mucin 5AC (Muc5AC). A small proportion of
IL33-positive epithelial cells also were Ki-67 positive. IL33 and
its receptor Interleukin 1 receptor-like 1 (ST2) were increased
4-fold after acute (1-day) H pylori infection, however, this in-
crease was not apparent after 7 days and IL33 expression was
reduced 2-fold after 2 months. Similarly, human biopsy speci-
mens positive for H pylori had a reduced IL33 expression.
Chronic IL33 treatment in mice caused systemic activation of
innate lymphoid cell 2 and polarization of macrophages to the
M2 phenotype. In the stomach, IL33-treated mice developed
transmural inﬂammation and mucous metaplasia that was
mediated by Th2/signal transducer and activator of transcrip-
tion 3 signaling. Rag-1-/- mice, lacking mature lymphocytes,
were protected from IL33-induced gastric pathology.
CONCLUSIONS: IL33 is highly expressed in the gastric mucosa
and promotes the activation of T helper 2–cytokine–expressing
cells. The loss of IL33 expression after prolonged H pylori
infection may be permissive for the T helper 1–biased immuneresponse observed during H pylori infection and subsequent
precancerous progression. (Cell Mol Gastroenterol Hepatol
2015;1:203–221; http://dx.doi.org/10.1016/j.jcmgh.2014.12.003)
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ecently, it was suggested that a class of specializedRimmune regulators, called alarmins, are involved in
activating an acute immune response after infection or
injury.1 Alarmins describe a class of multifunctional cyto-
kines released by necrotic cells in response to infection or
injury to promote an innate and adaptive immune
response.1 One such cytokine, interleukin 33 (IL33),2
enhances expression of T helper (Th)2 cytokines3 and ac-
tivates multiple immune regulatory cells including group 2
innate lymphoid cells (ILC2),4 basophils,5–7 mast cells,8
eosinophils,7 natural killer T cells,6 and Th2 lymphocytes.7
Current research on IL33 has focused mainly on its role in
lung pathology. However, IL33 also has been shown to provide
protection during gastrointestinal infection and dextran so-
dium sulfate–induced colitis by vigorously enhancing Th2
immunity.9–12 Collectively, these ﬁndings suggest that IL33
may be a crucial mediator of the immune response after dam-
age or infection in epithelial tissues. IL33 is highly expressed in
the stomach,3 however, little is known of its gastric function. In
this study,we addresswhich cells of the gastricmucosa express
IL33, how IL33 expression changes with damage and infection,
and characterize the function of IL33 in the stomach.
Similar to the lung and colon, the gastric mucosa is
vulnerable to chronic infection and inﬂammation, which may
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tion, intestinal metaplasia, and adenocarcinoma. The primary
causative agent in this regard is Helicobacter pylori. The ca-
pacity ofH pylori to colonize the gastricmucosa and promote a
favorable environment for gastric disease is highly dependent
on the response of the host immunity to insult and invasion.
IL33 is highly expressed in the gastric epithelium3 and
therefore may be an important factor in limiting H pylori
colonization and consequent inﬂammatory pathology. Despite
its disposition, a functional relationship between IL33
expression, H pylori infection, and resultant pathology has yet
to be described. Here, we address the role of IL33 during the
gastric immune response to the ulcerogen aspirin and in acute
and chronic H pylori infection. We show IL33 protein to be
localized predominately to the nuclei of a subset of surface
mucus cells (SMCs), and that systemic administration of IL33
causes a Th2-biased immune response in the stomach and
atypical gastric pathology. Furthermore, IL33 messenger RNA
(mRNA) is lost in human gastric samples positive for H pylori
and mice with prolonged H pylori infection; events that may
result in the skewed Th1/Th17 immunity observed during
H pylori infection and subsequent pathology.Materials and Methods
Cells
MKN28 cells were grown in RPMI media containing
10% fetal bovine serum (FBS), 100 mmol/L nonessential
amino acids (Sigma, St. Louis, MO), and 100 mmol/L
penicillin-streptomycin (Sigma). One hour before experi-
ments cell cultures were given fresh RPMI media containing
0.5% FBS.
Time course. Cells were given fresh media containing
100 ng/mL of recombinant human IL33 (Shenandoah, St.
Louis, MO). Media was left on cells for 0, 1, 5, 15, 30, or 60
minutes before cells were collected (n ¼ 3/time point). The
0-minute time point did not receive fresh media.
Dose response. Cells were given fresh media containing 0,
0.01, 0.1, 1, 10, or 100 ng/mL of recombinant human IL33
(Shenandoah) (n ¼ 3/concentration). Media was left on cells
for 5 minutes before cell harvest.
Cell harvesting. All cells were harvested using RIPA buffer
containing 2 nmol/L of sodium ﬂuoride, 2 nmol/L sodium
orthovanadate, and 1 protease inhibitor cocktail per 10 mL
of RIPA buffer solution (Roche Diagnostic, Indianapolis, IN).Mice
Wild-type (WT) mice were from a C57Bl/6 background,
10–12 weeks old. Most mice were housed in individually
ventilated, high-efﬁciency particulate absorption–ﬁltered
cages (speciﬁc pathogen free [SPF] conditions), and a small
subset of mice were kept in a different facility with covered,
but not individually ventilated, shoe box cages (conventional
conditions). All mice had autoclaved water and irradiated
food. Genetically modiﬁed mice were genotyped by multiplex
polymerase chain reaction (PCR) as previously described.13
Approval was obtained from Murdoch Children’s Research
Institute.Aspirin Treatment
WT mice (n  5) and trefoil factor (TFF)2-/- mice (n  4)
were treated with 300 mg (200 mL) of aspirin (Sigma) via an
oral gavage. Aspirin was suspended in 1% methylcellulose
aqueous solution (Sigma) and control mice were gavaged
with 200 mL of 1% methylcellulose. Mice were starved
overnight before aspirin administration. One hour after
treatment, mice were given food and killed either 4 or 24
hours after treatment.
Cytokine Treatment
WT mice (n  5) were injected intraperitoneally once
daily with 1 mg of recombinant human IL33 (Shenandoah)
or saline for 7 days. One hour before culling, mice were
given an additional dose of IL33.
Tissue Preparation
Mouse stomachs were prepared and analyzed as previ-
ously described.14 Half of the fundus and antrum were
collected in liquid nitrogen for RNA and protein. For histo-
logic examination, bisected tissue was ﬁxed in 4% para-
formaldehyde in phosphate-buffered saline. The spleen also
was collected for analysis. One half was frozen in liquid
nitrogen for RNA and protein. The second half was ﬁxed in
4% paraformaldehyde in phosphate-buffered saline.
Cell Isolation and Flow Cytometry (Fluorescence-
Activated Cell Sorting) Analysis
Spleen cell isolation. One third of the spleen was made
into a single-cell suspension. Red blood cells were lysed
with ammonium-Tris chloride buffer for 5 minutes at room
temperature. Cell suspensions were stained with ﬂuo-
rescently labeled antibodies (Supplementary Table 1) in
Hank’s balanced salt solution (HBSS) (2 mmol/L EDTA, 2%
FBS), washed, and resuspended in HBSS for ﬂuorescence-
activated cell sorter analysis (LSRII and FACSDiva v6.1.1;
Becton Dickinson, Franklin Lakes, NJ).
Stomach cell isolation. Stomachs were collected in HBSS
(2 mmol/L EDTA, 2% FBS), perfused with digestion media
(1  HBSS [without calcium and magnesium], 5 mmol/L
EDTA, 5% FBS, and 1 mmol/L dithiothreitol), and incubated
at 37C for 15 minutes. Stomachs then were cut and incu-
bated in digestion media for a further 15 minutes, and then
passed through a 70-mm cell strainer. Cell suspensions were
centrifuged and resuspended in 1  HBSS. Cells were
analyzed as described for spleen samples.
Fluorescence-activated cell sorter analysis. Dead,
autoﬂuorescent, and aggregated cells were removed from
the anlysis on the basis of forward scatter (FSC), side scatter
(SSC), and propidium iodide staining. The total number of
events for each cell type (Supplementary Table 1) was
quantiﬁed using CountBright beads (#36950; Invitrogen,
Carlsbad, CA).
Macrophage Isolation and Analysis
To harvest peritoneal macrophages, 5 mL of HBSS
(Sigma) containing 10 U/mL of heparin (Sigma) was
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cells were harvested, washed, resuspended in complete
RPMI, and then plated onto 6-well culture plates. Plates
were incubated at 37C for 10 minutes to allow macro-
phages to adhere. Cultures then were washed to remove
nonmacrophage cells. Macrophages were incubated over-
night at 37C. The next day, macrophage cultures were
treated with either saline or 100 ng IL33/mL in fresh media.
Cells were harvested using TRIzol reagent (Life Technolo-
gies, Carlsbad, CA).
Collection of Human Biopsy Specimens
Biopsy specimens were obtained with written consent
from the patients. Subjects’ histology and consent were
taken and exclusions were made as follows: use of poten-
tially damaging medications 4 weeks before biopsies,
mucosal injury or tumor, other comorbidities affecting the
gastric mucosa, or use of anticoagulants.15 Studies were
approved by the Melbourne Health Organisation
(#097.1998).
Quantitative Reverse-Transcription PCR
Total RNA was harvested using TRIzol reagent (Life
Technologies). RNA (3 mg) (n  5 animals/group) was
reverse-transcribed into complementary DNA using Molo-
ney murine leukemia virus reverse transcriptase (Promega,
Madison, WI) primed with oligo(dT). Quantitative reverse
transcription PCR (QRT-PCR) primers were designed using
Primer Express (Applied Biosystems, Foster City, CA)
(Supplementary Table 2). SYBR green chemistry was used
with rL32 as the internal reference gene. QRT-PCR condi-
tions were as follows: 95C for 10 minutes, 40 cycles of
95C for 15 seconds, and 60C for 15 seconds (AB7500;
Applied Biosystems). Results were analyzed using sequence
detector software, and relative fold differences were
determined using the DDCt method.
Immunoblotting
Proteins (n  5 animals/group) were prepared with
TRIzol (Life Technologies) and 20 mg of extract subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
Membranes were incubated with antibodies speciﬁc for
signal transducer and activator of transcription (STAT)3,
p-STAT3, extracellular signal–regulated kinase (ERK)1/2,
p-ERK1/2, nuclear factor-kB (NF-kB), glyceraldehyde-3-
phosphate dehydrogenase, b-actin (Supplementary
Table 3) (Abcam, Cambridge, UK), or peroxide-conjugated
secondary antibody, and visualized by enhanced chem-
iluminescence (Amersham, Buckinghamshire, UK). Quanti-
ﬁcation was performed using Quantity 1 software (Bio-Rad
Laboratories, Hercules, CA), and phosphorylated:total pro-
tein ratios were determined from duplicate membranes.
Immunohistochemistry
Parafﬁn sections (4 mm) on 3-aminopropyltriethoxysilane
slides were subject to immunohistochemistry according to
Supplementary Table 3. Antigen retrieval was performed with10 mmol/L citric acid at 100C for 30 minutes, followed by 30
minutes of cooling. Staining was completed with biotinylated
secondary antibodies, avidin, and biotinylated horseradish-
peroxidase complex (Vector Laboratories, Burlingame, CA),
and 3,3’-diaminobenzidine and hematoxylin counterstained.
For all staining reactions a control was performed with
secondary antibody alone. For immunoﬂuorescent staining,
sections were prepared as described and staining was
completed with ﬂuorescent-conjugated secondary antibodies
and cover slipped with Prolong Gold antifade-40,6-diamidino-
2-phenylindole mounting reagent (Invitrogen #P-36931).
Representative images from each treatment group are shown.
IL33 Enzyme-Linked Immunosorbent Assay
IL33 protein from mouse serum and stomach digests
were analyzed using IL33 enzyme-linked immunosorbent
assays (ELISAs) (eBioscience, San Diego, CA). For serum, 50
mL was used directly, whereas stomach digests were ﬁrst
analyzed by a Lowry assay and 30 mg of protein was diluted
into 50 mL. The procedure was performed according to the
manufacturer’s instructions.
Quantitative Morphometry
All quantitative morphometry was performed by a blin-
ded observer. Representative photos (n > 6) of each animal
(n> 5) of histochemically or immunohistochemically stained
sections were captured using a Coolpix 4500 digital camera
(Nikon Instruments, Melville, NY) attached to a light micro-
scope. Lengths of relevant cells were traced manually on
these images using ImageJ software for Windows v1.38
(http://rsb.info.nih.gov/ij/index.html; National Institutes of
Health, Bethesda, MD) to generate measurements. Measure-
ments were converted tomillimeters after comparisonwith a
calibrated graticule.
Statistical Analysis
All data were expressed as means ± SEM and statistical
analysis was performed using 1-way analysis of variance
and the appropriate parametric or nonparametric statistical
test using Sigmastat (Jandel Scientiﬁc, San Rafael, CA).
P values  .05 were considered statistically signiﬁcant.
Results
IL33 Expression Is Restricted to the Central
Nervous System and Epithelial Tissues
The BioGPS mouse microarray database was accessed to
compare the tissue distribution of IL33 expression (http://
biogps.org/#goto¼genereport&id¼77125) (Figure 1Ai).
The outcome of 2 independent microarray experiments
showed moderate to high expression of IL33 in the stomach,
brain, spinal cord, eye, epidermis, lung, and lymph nodes,
and low or no expression in the small and large intestines,
pancreas, bladder, kidney, heart, liver, and spleen
(Figure 1Ai). Therefore, the highest IL33 expression is found
in epithelial tissues and the central nervous system. Inter-
estingly, IL33 expression is not readily detectable in the
large intestine, an organ containing high bacterial load and,
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expression proﬁle of IL33 suggests that it may be critical in
regulating gastric homeostasis and preventing bacterial
overgrowth in the stomach, however, IL33 does not perform
these functions uniformly in the gastrointestinal tract.
Gastric IL33 mRNA Expression Is Dependent on
Bacterial Load
IL33 has been shown to reduce colonization and patho-
logic outcomes in murine models of intestinal infec-
tion,11,12,16 raising the prospect that it is a gut alarmin.
Because the disposition and function of IL33 in the stomach
is unknown, we initially investigated whether gastric bacte-
rial load inﬂuenced IL33 expression. To do so, gastric IL33
expression, as well its receptor, ST2, was compared in mice
housed in either SPF micro-isolator or conventional (ﬁlter
top) housing. Mice used in these experiments were born and
reared in their respective housing facility, and to ensure a
robust ﬁnding mice were compared from 3 cohorts that were
collected independently over the course of 12 months.
Gastric IL33 and ST2 mRNA expression were increased in the
conventional facility compared with the SPF facility
(Figure 1Aii). A eubacteria QRT-PCR on the 16S RNA tran-
script showed that the stomachs of mice derived from the
conventional housing facility had an increased and more
diverse bacterial load compared with those from the SPF
facility (Figure 1Aiii). These data suggest that, in the stomach,
IL33 expression is increased with bacterial load and di-
versity, consistent with an alarmin function for this cytokine.
IL33 Protein Is Localized to Surface Mucus Cells
Previous studies have shown that IL33 is detected in the
gastric epithelium.3,17 Immunoﬂuorescence showed that
IL33 is localized to the nucleus in a large subset of SMCs, in
particular those at the base of the gastric pits, rather than
directly in contact with the stomach lumen (Figure 1Bi). The
nuclear localization was conﬁrmed using 40,6-diamidino-2-
phenylindole counterstain (Figure 1Bi). IL33-/- mice were
used as controls, and no staining was observed in these
mice (Figure 1Bii). To additionally characterize IL33 locali-
zation to SMCs, IL33 immunoﬂuorescence was performed in
conjunction with the SMC markers UEA1 and Muc5AC
(Figure 1Ci and ii). IL33 protein expression was co-localized
with both SMC markers, conﬁrming our previous ﬁndings
(Figure 1Ci and ii). SMCs are in direct contact with the
stomach lumen and H pylori preferentially localizes to the
gastric pits, suggesting that IL33 is placed ideally to mount
an effective immune response after infection or injury.Figure 1. (See previous page). IL33 localization in the gastric
load and gastric insult. (Ai) Comparison of IL33 expression i
expression in the fundus of mice housed in either SPF or conven
(repeated 3 times). (Aiii) Eubacterial 16S expression in the SPF a
the gastric mucosa; (ii) IL33 immunoﬂuorescence on the gast
localization of IL33 with (i) UEA1, (ii) Muc5AC, and (iii) Ki-67 i
aspirin insult and IL33 protein localization at gastric ulcers (rep
week-old WT and TFF2-/- mice measured by QRT-PCR and E
cally signiﬁcant, P  .05. DAPI, 40,6-diamidino-2-phenylindole.Considering that IL33 resides within the nuclei of gastric
pit cells and is not directly in contact with the stomach
lumen we wanted to determine whether IL33 was
expressed by gastric pit cells, presurface mucous cells, or
progenitor cells. To address this we co-localized IL33 with
Ki-67 (Figure 1Ciii). Staining showed Ki-67–positive cells
were in close proximity with IL33-positive cells, and a small
proportion of cells were double positive for Ki-67 and IL33,
suggesting that IL33 is expressed by presurface mucous
cells and gastric pit cells (Figure 1Ciii).IL33 Is Increased After Gastric Damage That Is
Mediated Partially by TFF2
Alarmins are inﬂammatory mediators that respond
rapidly after insult or injury. Therefore, to determine
whether IL33 acts as a stomach alarmin, its expression and
distribution was measured after gastric insult. Mice were
given a single dose of aspirin (150 mg/kg in 1% methyl-
cellulose) by oral gavage to produce erosive gastric injury,18
and were culled either 4 or 24 hours after treatment.
Compared with WT controls, IL33 mRNA expression
increased 4 hours after injury (Figure 1D), and returned to
pre-injury levels within 24 hours (data not shown). In
addition, at erosive sites, IL33 protein was released from the
nucleus and localized to the cytoplasm in close proximity to
the apical membrane of the cell (Figure 1D). This shows that
IL33 responds immediately to gastric insult through re-
localization and transcriptional changes and may be
involved in gastric wound healing and restitution.
In the lung, the mucous cell homeostatic regulator TFF2
has been shown to drive IL33 expression.12 TFF2 is expressed
most highly in the gastric mucosa, and loss of TFF2 promotes
gastric pathology.19 To determine whether TFF2 also in-
ﬂuences gastric IL33 expression, steady-state IL33 mRNA
was measured in the gastric fundus of TFF2-/- mice at 12
weeks. In TFF2-/-mice, IL33mRNAexpressionwas decreased
substantially compared with WT controls (Figure 1E). In
addition, IL33 protein, quantiﬁed by ELISA assay, was
reduced by approximately 40% in TFF2-/- mice compared
with WT mice (Figure 1E). These ﬁndings show that, in the
stomach, IL33 expression is at least partly regulated by TFF2.IL33 Expression Is Increased in Response to
Acute H pylori Infection, but Is Suppressed in
Chronic Infection in Mice and Human Beings
To determine the consequences of acute and chronic H
pylori infection on IL33 expression, mice were infected withmucosa and mRNA expression increase owing to bacterial
n mouse tissues (repeated twice). (Aii) IL33 and ST2 mRNA
tional facilities as well as mouse gastric bacterial load (N  20)
nd conventional animal facility. (Bi) IL33 protein localization in
ric mucosa of IL33-/- mice (N ¼ 5) (repeated twice). (C) Co-
n the gastric mucosa (N ¼ 6). (D) IL33 mRNA 4 hours after
eated twice, N ¼ 6). (E) IL33 mRNA and protein levels in 12-
LISA assay, respectively (N ¼ 8) (repeated twice). *Statisti-
Figure 2. IL33 mRNA expression in the stomach increases after acute H pylori infection and steadily decreases with
more chronic infection. (A) IL33 mRNA expression after H pylori SS1 infection in mice; (i) 1 day, (ii) 7 days, and (iii) 2 months
relative to uninfected mice and standardized to the housekeeper L32 (N  6) (repeated twice). (B) IL33 mRNA expression in
human biopsy specimens positive for H pylori infection relative to uninfected biopsy specimens and standardized to the
housekeeper L32; (i) antrum and (ii) midbody (N  12). (C) Co-localization of IL33 with UEA1 in H pylori–SS1–infected mice: (i)
control, (ii) 7 days, and (iii) 2 months (N ¼ 5). (D) mRNA expression of (i) Muc5AC and (ii) TFF2 after 1 day, 7 days, and 2 months
of H pylori–SS1 infection, and standardized to the housekeeper L32 (N  6). (E) Expression of the ILC2 genes: (i) RORa, (ii)
amphiregulin, and (iii) IL13 after 1 day, 7 days, and 2 months of H pylori–SS1 infection, and standardized to the housekeeper
L32 (N  6). *Statistically signiﬁcant, P  .05.
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months, and IL33 mRNA was quantiﬁed by QRT-PCR. After 1
day of infection, IL33 mRNA expression was increased
relative to uninfected controls (Figure 2Ai). IL33 mRNA
expression still was increased 7 days after H pylori–SS1
infection, however, this increase was less than that observed
in the 1-day cohort, and was not signiﬁcantly different from
controls (Figure 2Aii). Two months of H pylori–SS1 infection
resulted in a signiﬁcant reduction in IL33 mRNA expression
(Figure 2Aiii). To extend our understanding of the interplay
between IL33 expression and H pylori infection we collected
human gastric biopsy specimens from individuals chroni-
cally infected with H pylori and uninfected controls. IL33
mRNA expression was decreased in the H pylori–positive
antrum and midbody when compared with control biopsy
specimens (Figure 2B). These data show that IL33 mRNA
expression is induced rapidly after acute H pylori infection,
and then suppressed with prolonged infection. Furthermore,
we have shown that the effect of chronic H pylori infection
on IL33 mRNA expression is similar in human beings and
mice. These data are consistent with an alarmin function for
IL33 in the stomach.
To determine whether reduced IL33 expression during
chronic H pylori–SS1 infection was caused by loss of SMCs
we performed IL33 and UEA1 immunoﬂuorescence on the
stomach of 7-day and 2-month H pylori–SS1–infected mice
(Figure 3C). H pylori infection (2 months), if anything, caused
a slight increase in the amount of UEA1 staining, suggesting
that at this time point H pylori infection increased SMCs and
therefore reduced IL33 expression is independent of this
process. In support of this ﬁnding mRNA expression of
Muc5AC and TFF2 also was not affected by H pylori infection
(Figure 2Di). These data suggest that H pylori–SS1 may act
directly to suppress IL33 expression.
IL33 recently was reported to induce activation of ILC2,4
therefore we assessed whether altered IL33 mRNA expres-
sion duringHpylori–SS1was sufﬁcient to alter the expression
of the ILC2 genes, RAR-related orphan receptor alpha (RORa),
amphiregulin, IL13, and GATA3 (Figure 2E). The mRNA
expression of RORa and amphiregulin was not changed after
1 or 7 days of H pylori–SS1 infection (Figure 2Ei and ii).
However, bothwere decreased after 2months ofHpylori–SS1
infection (Figure 2Ei and ii). In contrast, IL13 was not
changed (Figure 2Ei), and neither was GATA3 (data not
shown). To assess the speciﬁcity of these gene changes RORa,
amphiregulin, IL13, and GATA3 also were assessed in the
spleen afterHpylori–SS1 infection. Therewas no difference in
the mRNA expression of these genes at any time point tested
(1 day, 7 days, 2 months, and point tested data not shown).Figure 3. (See previous page). The gastric mucosa is respo
responsiveness of MKN28 cells to IL33 assessed through anal
dependent responsiveness of MKN28 cells to IL33 assessed th
(C) IL33 protein levels in sera ofmice treatedwith IL33 for 7 daysm
STAT3 relative to total protein in the antrum and fundus of mice 2
ERK1/2, NF-kB, and STAT3 relative to the housekeeping protein
days. (F) Amount of phosphorylation protein of ERK1/2, NF-kB,
antrum and fundus of mice treated with IL33 for 7 days. Salin
*Statistically signiﬁcant, P  .05. P.O.I., protein of interest.Gastric Epithelial Cells Are Responsive
to IL33 In Vitro
To determine the nature of the downstream signaling
pathways activated in the stomach in response to IL33
treatment, a dose response and time course of signal acti-
vation in the human gastric cancer cell MKN28 was per-
formed for up to 60 minutes. Activation pathways
culminating in phosphorylation of NF-kB, ERK1/2, Akt, and
STAT3 were evaluated. IL33 treatment did not alter the
total expression or phosphorylation of these pathway me-
diators (data not shown), apart from ERK1/2. In dose-
response experiments, MKN28 cells showed a progressive
increase in pERK1/2, with increasing IL33 concentration
(Figure 3A). Subsequently, MKN28 cells were treated with
100 ng IL33/mL in time course studies, and cells were
harvested at time points from 0 to 60 minutes. MKN28 cells
showed a peak of phosphorylated EKR1/2 after 5 minutes
of IL33 treatment, followed by a rapid decrease to near-
basal levels by 60 minutes (Figure 3B). These data show
that the gastric cell line MKN28 is responsive to acute IL33
and that signaling is dependent predominantly on phos-
phorylated ERK1/2.Acute Administration of IL33 In Vivo Selectively
Activates ERK1/2, and Chronic IL33 Activates
STAT3 in the Gastric Mucosa
To understand the responsiveness of the whole stomach
to IL33, mice were treated systemically with 1 mg of recom-
binant mouse IL33 daily by intraperitoneal injection, for
either 24 hours (acute) or 7 days (chronic). Quantiﬁcation of
IL33 protein by ELISA in the serum of mice treated for 7 days,
showed a 9-fold increase in circulating IL33 compared with
basal levels in saline controls (Figure 3C). Acute adminis-
tration of IL33 increased phosphorylated ERK1/2 to total
ERK1/2 ratio by 46% in the antrum, whereas NF-kB and
STAT3 were unchanged (Figure 3D). No changes in signaling
were observed in the fundus (Figure 3D). After chronic IL33
treatment, the amount of total ERK1/2 to b-actin ratio was
unchanged in the fundus or antrum (Figure 3E). However,
there was an increase in the ratio of total NF-kB to b-actin as
well as STAT3 to b-actin at this time point) (Figure 3E).
Relative to the housekeeping protein, b-actin, phosphory-
lated ERK1/2, and phosphorylated NF-kBwere unchanged in
both the antrum and fundus (Figure 3F). In contrast, the ratio
of phosphorylated STAT3/b-actin was increased substan-
tially in both the antrum and the fundus (Figure 3F). These
data suggest that IL33-mediated signaling pathways differ
temporally in the gastric mucosa, with phosphorylatednsive to IL33 both in vitro and in vivo. (A) Dose-dependent
ysis of ERK1/2 activation (N ¼ 3) (repeated twice). (B) Time-
rough analysis of ERK1/2 activation (N ¼ 3) (repeated twice).
easured by ELISA. (D) Phosphorylation of ERK1/2, NF-kB, and
4 hours after IL33 administration. (E) Amount of total protein of
b-actin in the antrum and fundus of mice treated with IL33 for 7
and STAT3 relative to the housekeeping protein b-actin in the
e, n ¼ 10; IL33, n ¼ 9; experimented was repeated 3 times.
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STAT3 induced chronically. In this context, hyperactivated
STAT3 has been shown to be associated with progressive
gastric inﬂammation and metaplasia.18Chronic IL33 Application Causes Inﬂammation,
Atypical Metaplasia, and Hypoproliferation
of the Gastric Mucosa
The stomach can be separated into 3 distinct gland types
and/or regions according to the composition of gastric
epithelial cells residing within each area: (1) the cardiac
glands at the gastroesophageal junction, (2) the acid-
secreting fundic glands that encompass the central portion
of the stomach, and (3) the mucus-secreting antral glands
that are most distal. Chronic IL33 treatment induced histo-
pathologic changes in all 3 regions (Figure 4A–C). In a normal
mouse stomach the cardiac glands are restricted to a very
discrete group of Alcian blue (AB)–stained cells, indicative of
acidic mucin secretion (Figure 4A, arrow). After IL33 treat-
ment, the cardiac glands became disorganized, with an
increased proportion of acidic mucin-producing cells in this
region. This morphology was associated commonly with
cystic dilatation in the adjacent fundus (Figure 4A).
AB–periodic acid–Schiff (PAS) staining in the antrum showed
a near-total loss of PAS-positive (neutral mucins) staining in
IL33-dosed stomach sections in the surface and pit cells, and
an increase in acidic mucins in cells at the base of the glands
(Figure 4B). In the fundus, AB-PAS staining of IL33-treated
stomachs highlighted atrophy, necrosis, metaplasia, inﬂam-
mation, and thickening of the muscularis, with a distinct
metaplasia characterized by an expanded population of PAS-
expressing cells in the midregion of the glands, and a loss of
mucin staining in SMCs (Figure 4C).
To better characterize the pathology observed in the
stomach after chronic IL33 treatment, morphologic indices
of inﬂammation, atrophy, and metaplasia were measured
semiquantitatively. Assessment of immune inﬁltrate showed
an increase in polymorphonuclear and lymphoplasmocytic
inﬁltrate in the fundus, which was accompanied by atrophy
and mucous metaplasia (Figure 4C). Atrophy was conﬁrmed
by HþKþ adenosine triphosphatase b staining, which showed
a reduction in the number of parietal cells per fundic gland of
IL33-treated mice (Figure 4D). Ki-67 staining showed a
reduced number of proliferating cells in fundic glands
(Figure 4E). In addition to this, a redistribution of Ki-
67–positive cells from the neck region (Figure 4E, brackets)
to the base of the glands and in the muscularis ofFigure 4. (See previous page). IL33 treatment causes atypic
region of the stomach between saline- and IL33-treated mice. (B
treated mice. (C) AB-PAS comparison of the fundus between sa
of gastric inﬂammation, atrophy, and metaplasia. (D) Assessm
antibody directed to Hþ/Kþ adenosine triphosphatase b subun
immunohistochemistry using antibody directed to Ki-67. (F) Asse
antibody directed to intrinsic factor. (G) Assessment of mast c
antibody directed to mast cell chymase and mRNA expression
treated mice and standardized to the housekeeper L32. Salin
*Statistically signiﬁcant, P  .05. Tx, treatment.IL33-treated mice was observed (Figure 4E, arrow). How-
ever, these Ki-67–positive cells appear to be inﬁltrating
immune cells and not epithelial cells. To further deﬁne
IL33-induced gastric pathology we performed immunohis-
tochemistry for intrinsic factor, a marker of chief cells in
mice, on 7-day IL33-treated mice (Figure 4F). In saline-
treated mice there was obvious intrinsic factor staining of
chief cells at the base of the gland, however, this staining was
lost after IL33 treatment, reinforcing the observation that
systemic administration of IL33 can cause gastric atrophy
(Figure 4F).
In IL33-treated mice, mast cell inﬁltrate, deﬁned by
staining for mast cell chymase, was increased in the fundic
mucosa (Figure 4F). In addition, mRNA expression of the
mast cell markers, chymase and tryptase, were increased in
the fundus of chronic IL33-treated mice (Figure 4F). There
was no change in cell apoptosis as assessed by staining for
activated caspase-3 (data not shown). These data show that
prolonged exposure to IL33 has selective and profound ef-
fects on the gastric mucosa, including stasis of proliferation,
loss of neutral mucin production in surface and pit cells,
mucinmetaplasia in antral and fundic glands, and an increase
in inﬂammatory cells including mast cells. This emphasizes
the potential key regulatory activity of IL33 in the stomach.
Chronic IL33 Administration Promotes Myeloid
Cell Accumulation in the Spleen
Initially, we measured the effects of systemic adminis-
tration of IL33 on the peripheral immune system through
analysis of the effects of IL33 on the spleen. IL33 is known to
cause splenomegaly.3 Here, we expand on the mechanism by
which IL33 can cause splenomegaly and the implication of
this on gastric immune responses. After acute and chronic
administration of IL33 we observed an increase in spleen
weight of 50% after 24 hours and 120% after 7 days
(Figure 5A). Flow cytometry was used to assess the effects of
IL33 treatment on immune cell populations. The leukocytes
were separated into 3 clear populations on the basis of their
morphology: small size and low complexity (granularity)
being predominantly lymphocytes, intermediate size and
complexity, and high size and complexity. The last 2 pop-
ulations are indicative of either myeloid cells or increased
cellular activation. After IL33 treatment the spleen showed a
decrease in the proportion of cells in the lymphocyte popu-
lation and an increase in the proportion of larger and more
highly complex cell populations (Figure 5B). In IL33-treated
mice the total number of splenic CD4þ helper T cells, CD8þ
cytotoxic T cells, and CD45Rþ B cells were not changedal gastric pathology. (A) AB-PAS comparison of the cardiac
) AB-PAS comparison of the antrum between saline- and IL33-
line- and IL33-treated mice, and semiquantitative assessment
ent of parietal cell atrophy with immunohistochemistry using
it. (E) Assessment of proliferation in the fundic glands with
ssment of chief cell atrophy with immunohistochemistry using
ell inﬁltrate in the fundus with immunohistochemistry using
of mast cell markers in IL33-treated mice relative to saline-
e, n ¼ 10; IL33, n ¼ 9; experiment was repeated 3 times.
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total number of splenic CD11bþLy6C/GNEG-LOW macro-
phages, CD11bþLy6C/GINT myeloid derived suppressor cells
(MDSCs), CD11bþLy6C/GHIGH neutrophils, and CD11cþ den-
dritic cells (DCs) all were increased signiﬁcantly (Figure 5Cii
and iii). Lineage-negative cells (CD4/8/11b/11c/45R/Ly6C/
GNEG), which include ILCs, also were quantiﬁed; and the total
number of lineage-negative cells were increased in the spleen
of IL33-treated mice (Figure 5Civ). In summary, IL33
administration causes an increase in the total number of
splenic macrophages, neutrophils, and DCs, as well as
lineage-negative cells, whereas T- and B-cell populations
were not expanded.
We quantiﬁed ILC activation by measuring characteristic
marker genes23 in the spleen after chronic administration of
IL33 (Figure 5Di–iii). After chronic IL33 administration the
ILC1 markers interferon-g and tumor necrosis factor-a
were decreased, whereas RORgt, a marker of ILC1 and ILC3,
was not changed (Figure 5Di). In contrast, all ILC2 markers
were increased in IL33-treated spleens compared with sa-
line controls, including amphiregulin, IL5, IL9, and IL13
(Figure 5Dii), whereas RORa and GATA3 trended to increase
but failed to reach statistical signiﬁcance. Similar to ILC1, no
differences were observed in the ILC3 markers RORg, IL22,
IL23, and IL17A (Figure 5Diii). These data show the ability
of IL33 to speciﬁcally activate ILC2 to promote a Th2-biased
response in the spleen.IL33 Polarizes Macrophages to the Alternatively
Activated M2 Class
Macrophages are pivotal immune cells that participate in
both the innate and adaptive immune response. In the lung,
IL33 activates M2 macrophages leading to ﬁbrosis,20 in
addition there is precedent for macrophages playing an
important role in the pathologic response of the gastric mu-
cosa.21 Certain classes of macrophages have been shown to
accelerate tumor progression22 and it now is accepted that,
similar to T cells, a combination of effector signals can pro-
mote a macrophage to become polarized into either M1 or
(alternatively activated) M2 class, differentiated by expres-
sion of speciﬁc Th1 or Th2 inﬂammatory markers.23 There-
fore, peritoneal macrophages from chronic IL33-treatedmice
were isolated and M1 and M2 markers were quantiﬁed.
Overall, mRNA expression of M1-associated genes were
decreased uniformly including tumor necrosis factor, induc-
ible nitric oxide synthase, IL1a, IL1b, and IL12 (Figure 5Ei). In
contrast, the expression of M2 genes was increased including
IL4, IL5, and IL13 (Figure 5Eii). Additional M2 genes alsoFigure 5. (See previous page). Effects of IL33 on the spleen an
and 7 days of IL33 treatment. (B) Size and complexity of immun
with saline controls. (C) Total number of immunocyte types in th
(i) CD4þ, CD8þ, and CD45Rþ; (ii) CD11bþLy6C/GLOW-NEG, CD1
lineage-negative immunocytes (saline, n ¼ 6; IL33, n ¼ 5). (D) mR
treated mice all expressed relative to saline-treated mice and sta
group 2 ILC markers; and (iii) group 3 ILC markers. (E) Assessm
IL33 treatment all expressed relative to saline-treated mice and
markers, (iii) markers of antigen-presenting cells (APCs). Saline
tistically signiﬁcant, P  .05. FSC, forward scatter; iNOS, inducwere increased in IL33-treated macrophages including Ym1,
Ym2, transforming growth factor-b, and FIZZ1 (Figure 5Eii).
A second distinguishing feature of macrophages is their
ability to present antigens through the major histocompati-
bility complex. Major histocompatibility complex genes
H2-Aa, H2-ab1, H2-Ea, and H2-Eb1 all were decreased in
IL33-treated macrophages (Figure 5Eiii). These data suggest
that IL33-exposed peritoneal macrophages are polarized to
an M2 phenotype and have a reduced capacity to present
antigens.
IL33 Promotes Expansion of Myeloid-Derived
Immunocytes in the Stomach
We previously showed that IL33 promotes expansion of
myeloid-derived immunocytes in the spleen (Figure5B andC),
therefore we wanted to determine whether immunocyte
populations were altered similarly in the stomach. Stomach
immunocyte populations were assessed using ﬂuorescence-
activated cell sorter analysis and the total cell number per
stomach is shown in Figure 6A. Similar to the spleen, IL33-
treated stomachs showed no differential in the number of
CD4þhelperT cells, CD8þ cytotoxic T cells, andCD45RþBcells
(Figure 6Ai). Consistent with the spleen there was an increase
in the total number of stomach CD11bþLy6C/GNEG-LOW mac-
rophages, CD11bþLy6C/GINT MDSCs, CD11bþLy6C/GHIGH
neutrophils, and CD11cþ DCs (Figure 6Aii), however, we
observed no expansion of lineage-negative cells (Figure 6Aiv).
These data show that IL33 promotes the expansion of
myeloid-derived immunocytes in the stomach.
IL6 May Induce STAT3 Activation After Chronic
Administration of IL33
IL33 does not directly promote STAT3 activation in a
human gastric cell line (Figure 3A and B) or in the stomach
after acute administration; however, STAT3 is activated
in vivo after 7 days of IL33 administration (Figure 3D–F). To
determine the identity of the indirect activator of STAT3 in
IL33-treated stomachs, we quantiﬁed the 2 main gastric
gp130/STAT3 ligands, IL6 and IL11, as well as the negative
regulator of STAT3 signaling, suppressor of cytokine
signaling 3. Acute administration of IL33 caused IL6 mRNA
to be increased in both the antrum and fundus by 2- to
4-fold (Figure 6B), whereas IL11 mRNA was decreased
throughout the stomach (Figure 6B). After 7 days of IL33
treatment, IL6 preferentially was activated (Figure 6B).
These data show that IL6 expression is induced downstream
of both acute and chronic IL33 administration, and may be a
key activator of STAT3 after IL33 treatment.d peritoneal macrophages. (A) Spleen weight after 24 hours
e cells in the spleen after 7 days of IL33 treatment compared
e spleens of IL33-treated mice compared with saline controls:
1bþLy6C/GINT, and CD11bþLy6C/GHIGH; (iii) CD11cþ; and (iv)
NA expression of markers of ILC in the spleen of 7-day IL33-
ndardized to the housekeeper L32: (i) group 1 ILC markers; (ii)
ent of peritoneal macrophage mRNA expression proﬁle after
standardized to the housekeeper L32: (i) M1 markers, (ii) M2
, n ¼ 10; IL33, n ¼ 9; experiment was repeated twice. *Sta-
ible nitric oxide synthase; SSC, side scatter; Tx, treatment.
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mRNA expression of the IL1 family cytokines IL1a, IL1b,
IL33, and its receptor ST2 were measured to assess the
inﬂammatory response in the stomach after exogenous IL33
treatment. In the antrum of acute IL33-treated mice there
was an increase in IL33, ST2, IL1a, and IL1b (Figure 6C),
however, this response was suppressed with chronic treat-
ment, with IL33 and ST2 only marginally increased and IL1a
and IL1b unchanged (Figure 6C). A similar outcome was
observed for the fundus (Figure 6C).
IL33 promotes the expansion of myeloid-derived cells in
the stomach (Figure 6A), however, it previously was re-
ported that IL33 can activate ILC2 and Th2 immunocytes,
and thus initiate a Th2 cytokine response.4 Therefore, to
assess whether IL33 could activate ILC2 and Th2 immuno-
cytes in the stomach (Figure 6A), we quantiﬁed the mRNA
expression of types 1, 2, and 3 ILCs in the stomachs of mice
treated with IL33 for 7 days. A very similar response was
observed in both the antrum and fundus, although the
magnitude of the response in the former with respect to
ILC2 markers was 10-fold greater than in the latter. In both
mucosae, markers for ILC1 and ILC3 were unchanged in
response to IL33 (Figure 6D), however, the ILC2 markers
IL5, IL9, and IL13 all were increased greatly in their mRNA
expression (antrum 200- to 1000-fold, Figure 6D; and
fundus 15- to 23-fold, Figure 6E), whereas RORa, GATA3,
and amphiregulin were increased only marginally
(Figure 6D and E). In addition, the Th2 cytokine, IL4, also
strongly was up-regulated in both antrum and fundus (13-
to 26-fold, Figure 6F) co-incident with the strong gastric
Th2 response to IL33. These ﬁndings show IL33 to be
multifunctional in inﬂuencing the gastric immune response,
and that prolonged exposure to IL33 results in a Th2-biased
response indicative of Th2 lymphoid-derived cell and ILC2
activation, despite these immunocyte populations not being
expanded in the stomach (Figure 6A). Furthermore, IL9 can
induce STAT3 phosphorylation,24,25 and therefore, along
with IL6, may contribute to the increase in phosphorylated
STAT3 observed in these mice.
IL33-Induced Gastric Pathology Is Dependent on
Mature Lymphoid-Derived Cells
After chronic IL33 treatment, WT mice develop gastric
metaplasia and hypoplasia with characteristic loss of surface
mucins and glandular mucous metaplasia. IL33 gastropathy
is associated with marked activation of Th2 lymphocytes andFigure 6. (See previous page). Immunocyte populations i
expression proﬁle of ligands and regulators of gp130, IL1 cy
and 7-day IL33-treated mice. (A) Total number of immunocyt
saline controls: (i) CD4þ, CD8þ, and CD45Rþ; (ii) CD11bþLy6C
CD11cþ; and (iv) lineage-negative immunocytes (saline, n ¼ 6
antrum and fundus of 24-hour and 7-day IL33-treated mice all
the housekeeper L32. (C) mRNA expression of IL1 family cyto
treated mice. (D) Antrum and (E) fundus, expression of ILC ma
(iii) group 3 ILC markers. (E) IL4 expression in the antrum and
relative to saline-treated mice and standardized to the housek
twice. *Statistically signiﬁcant, P  .05.ILC2 and activation and expansion M2 macrophage recruit-
ment, shown by ﬂuorescence-activated cell sorter analysis
and mRNA expression proﬁles. To clarify which immunocyte
population promotes this mucosal response, Rag-1-/- mice,
which lack mature lymphocytes including B, T, and natural
killer T cells,26 but develop normal myeloid and ILC lineages,
were treated with IL33 or saline for 7 days by intraperitoneal
injection. IL33-treated Rag-1-/- mice had a doubling of spleen
weight compared with littermate controls, consistent with
ﬁndings inWTmice (Figure 7A). They also showed a decrease
in lymphocyte populations and an increase in intermediate
and high complex cell populations (Figure 7B). These cell
population changes were similar to those of IL33-treatedWT
mice (Figure 5B). Despite this, Rag-1-/- mice showed no evi-
dence of gastric metaplasia or inﬁltration of immunocytes
after IL33 treatment, suggesting that lymphocytes are
required for IL33-induced gastric pathology (Figure 7C). In
WT mice, STAT3 activation coincided with high IL6 and IL9
mRNA expression. IL6, and particularly IL9, are produced by
T cells; therefore, it is most likely that T cells drive IL33-
mediated Th2/STAT3 gastric pathology.
Discussion
IL33 now is recognized as an alarmin, capable of
responding to adverse circumstances such as infection or
mucosal damage in the lung and colon, and can promote
Th2 immunity.2 Similar to the lung and colon, the stomach
epithelium requires a stringent, balanced immune response
to ensure homeostasis, and dysfunctional immunity can lead
to disease progression, such as that after H pylori infection.
We have shown that IL33 ideally is expressed in gastric pit
mucous cells to modulate local immune responses. In
addition to being localized to gastric pit cells, a small
portion of IL33-positive cells were co-localized with Ki-67.
This suggests that IL33 is expressed once progenitor cells
begin to differentiate into presurface mucous cells and IL33
continues to be expressed by SMCs within gastric pits.
However, as SMCs continue to mature and migrate toward
the tips of the glands, IL33 is suppressed (Figure 2C). This
loss of IL33 may be important in preventing inappropriate
activation of gastric immunity. We also show that IL33 can
be induced acutely in response to bacterial antigen chal-
lenge and epithelial damage. Collectively, the data show that
IL33 is a stomach alarmin. In addition, IL33 expression is
increased chronically when the environmental bacterial load
is increased, suggesting that it plays an important role in
maintaining correct luminal microbiota.n the stomach of 7-day IL33-treated mice and mRNA
tokines, and ILC markers in the gastric mucosa of 24-hour
e types in the stomach of IL33-treated mice compared with
/GLOW-NEG, CD11bþLy6C/GINT, and CD11bþLy6C/GHIGH; (iii)
; IL33, n ¼ 5). (B) mRNA expression of gp130 ligands in the
expressed relative to saline-treated mice and standardized to
kines in the antrum and fundus of 24-hour and 7-day IL33-
rkers: (i) group 1 ILC markers; (ii) group 2 ILC markers; and
fundus of 7-day IL33-treated mice. All values are expressed
eeper L32. Saline, n ¼ 10; IL33, n ¼ 9; experiment repeated
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expression is increased acutely after H pylori infection in
mice; however, its expression is decreased 2 months after
infection. Similarly, IL33 is lost in human H pylori–positive
biopsy specimens compared with negative biopsy speci-
mens. Chronic H pylori infection exacerbates Th1/Th17
inﬂammation, at the expense of Th2 immunity, leading to
disease progression (Figure 7Di). This skewed immunity
during prolonged H pylori infection is well established as
fundamental for gastric carcinoma development, suggesting
that the loss of Th2 immunity contributes signiﬁcantly to
disease progression. IL33 recently was shown to modulate
the function of regulatory T cells in the intestine.27 Regu-
latory T cells are potent immune suppressors and although
their abundance in gastric tumors negatively correlates to
patient survival, increased levels of the regulatory T-cell
protein, FoxP3, a marker of regulatory T-cell activity, within
gastric cancer cells coincides with a good prognosis.28 In
addition, FoxP3 has been shown to reduce tumor growth.28
Therefore, IL33 may inhibit H pylori–induced gastric disease
by enhancing regulatory T-cell function, but not expansion.
Furthermore, under circumstances in which Th2 immunity
is increased during H pylori infection, such as co-infection
with gut parasites, resultant gastric pathology is reduced,
or does not eventuate.29 In addition, some human pop-
ulations with a high gut parasite burden but equivalent
levels of H pylori infection have a reduced incidence of
gastric cancer.30 This suggests that mechanisms that pro-
mote Th2 immunity can limit the development of H pylo-
ri–induced gastric pathology. Therefore, the inhibition of
gastric IL33 in response to chronic H pylori infection may be
a key event in gastric cancer progression by preventing
induction of Th2 immunity, and skewing the local immune
response to Th1/Th17 (Figure 7Di).
TFF2 expression is required for normal basal IL33
expression in the lung.12 Similar to the lung, loss of TFF2
causes a reduction in IL33 expression in the stomach,
showing that IL33 is regulated at least partially by TFF2.
Similar to IL33, TFF2 expression is lost during chronic H
pylori infection in human beings, and its expression de-
creases progressively as cancer advances.19 Furthermore,
TFF2 is crucial for maintaining gastric gland integrity and
repair,31,32 a function to which IL33 also may contribute, as
shown by the release of IL33 at sites of injury after aspirin
insult. In addition, TFF2 null mice spontaneously develop
gastric pathology and are more susceptible to H pylori
infection than WT mice.33 Pathologic outcomes in this
mouse model may develop owing to reduced IL33 expres-
sion, particularly in the setting of H pylori infection, in which
TFF2 null mice may have reduced IL33/Th2 immunity.
Interestingly, during H pylori infection, loss of IL33
expression does not correlate to a loss of SMCs or TFF2Figure 7. (See previous page). Effects of IL33 on the splee
weight of IL33-treated Rag-1-/- mice. (B) Size and complexity of i
(C) AB-PAS staining of the fundus of Rag-1-/- mice. WT-saline,
n ¼ 6. (D) Summary of immunologic changes and gastric patho
*Statistically signiﬁcant, P  .05. SSC, standard saline citrate.expression, suggesting that H pylori may suppress IL33
directly. It also is possible that IL33 is regulated by addi-
tional gastric-associated genes besides TFF2. Considering
that IL33 is expressed in SMCs, functions as an alarmin, and
appears to regulate gastric homeostasis and wound healing,
it is plausible to suggest that gastric homeostatic genes,
necessary for normal gastric function, such as TFF1 and
gastrokines 1 and 2, also may inﬂuence IL33 expression, and
altered expression of these and other genes during chronic
H pylori infection may cause a decrease in IL33 expression.
Although we show here that IL33 is decreased after
chronic H pylori infection, it recently was reported that IL33
serum levels are increased during gastric cancer.34 Sun
et al34 observed a positive correlation between IL33 serum
levels and cancer severity, with individuals with the highest
IL33 serum levels having the most aggressive cancers with
metastatic properties. This suggests that IL33 serum levels
may be a potential biomarker for gastric cancer. Although
this is a highly interesting ﬁnding, it is worth noting that
increased serum IL33 levels were typically in the setting of
metastatic gastric cancer and it is not clear if the source of
IL33 in this setting was gastric in origin. In contrast, here we
clearly have shown the capacity of IL33 to act as a stomach
alarmin and provide evidence to suggest that its suppres-
sion during H pylori infection may inﬂuence disease
progression.
Acute and chronic IL33-treated mice present with
increased spleen weight as previously reported.35 Acute
administration was consistent with alarmin function; that is,
activation of ERK1/2 in the gastric mucosa and increased
expression of innate cytokines, IL1a, IL1b, and IL6 shows
the capacity of IL33 to mediate gastric inﬂammation and act
as a stomach alarmin. In contrast, chronic administration
caused a distinctly different outcome. ERK1/2 was no
longer activated, and expression of IL1a or IL1b was not
increased. However, STAT3 was highly activated, leading to
Th2-mediated gastric metaplasia, suggesting that IL33 may
be capable of driving gastric disease under speciﬁc cir-
cumstances. In IL33-treated mice, the fundus was atrophic
(Figure 7Dii), and the cardiac stomach was greatly expanded
and metaplastic. Such cardiac stomach pathologies have
been associated with progression to Barrett’s esophagus, a
precursor of esophageal cancer.36 The incidence of Barrett’s
esophagus is increasing steadily, coincident with a gradual
decrease in H pylori infections and gastric cancer
incidence.37–39 In addition, H pylori colonization also has
been shown to protect against Barrett’s esophagus.37–39
Therefore, IL33 may promote cardiac pathology leading to
Barrett’s esophagus, and H pylori may protect against Bar-
rett’s esophagus by suppressing IL33/Th2 immunity. This
highlights the importance of balanced gastric immunity.
Although we suggest that the loss of IL33 expression duringn and stomach of lymphocyte-deﬁcient mice. (A) Spleen
mmune cells in the spleen of 7-day IL33-treated Rag-1-/- mice.
n ¼ 6; WT–IL33, n ¼ 6; Rag-1-/-–saline, n ¼ 6; Rag-1-/-–IL33,
logy after (i) H pylori infection or (ii) 7 days of IL33 treatment.
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pathology, we also show that excessive IL33/Th2 immunity
can drive pathology. Furthermore, despite the immune
response being vastly different (H pylori induces a Th1/
Th17 biased response while IL33 induces a Th2 biased
response), the outcome appears to be similar because pre-
neoplastic changes occur in both settings (Figure 7D). In
keeping with recent ﬁndings,37–39 these data suggest that H
pylori may be a beneﬁcial organism that under certain cir-
cumstances may help to ensure that gastric immunity is
tightly regulated.
Flow cytometric analysis of spleen tissue showed that
IL33-treated mice had a marked increase in neutrophils,
MDSCs, DCs, and macrophages. In addition, IL33 adminis-
tration caused activation of ILC2s in the spleen, as shown by
the increase in size and complexity of lineage-negative cells
and an increase in mRNA expression of ILC2- and Th2-
associated genes. Neutrophils, MDSCs, DCs, and macro-
phages also substantially were increased in the stomach after
IL33 treatment, as were ILC2- and Th2-associated genes.
ILC2s are inﬂuential in modulating immunocytes during
infection and lymphoid cell development by driving Th2
activation, macrophage polarization, and promoting B-cell
production, and are necessary for T-cell development, high-
lighting their importance for mounting a successful Th2 im-
mune response to infection.40,41 Our data show that IL33
promotes ILC2 activation in both the spleen and stomach
(summarized in Figure 7D), which coincides with morpho-
logic changes in the gastric mucosa (Figure 7Dii), including
the accumulation of mast cells, which previously were shown
to associate with metaplasia in other tissues, particularly in
the lung.42,43 IL33 also caused the polarization of peritoneal
macrophages to the M2 phenotype, expressing high levels of
IL4, IL5, and IL13. M2 macrophage populations are recog-
nized as tumor-associated macrophages and can drive car-
cinomas.44,45 Therefore, by analogy, it is reasonable to
suggest that IL33 may promote differentiation and accumu-
lation in the stomach of M2 macrophages, which also
contribute to IL33-induced gastric pathology.
Although gastric pathology appears to be dependent on
STAT3 activation rather than NF-kB– or ERK1/2-mediated
signaling, we have shown that IL33 does not activate
STAT3 directly. This suggests that IL33-induced gastric pa-
thology is dependent on inﬁltrating immune cells, which in
turn induce STAT3, leading to gastropathy. In chronic IL33-
treated WT mice, the established STAT3 inducers, IL6 and
IL9, were highly up-regulated in the stomach. Although IL6
commonly is secreted bymost immunocytes, recent work has
suggested that IL9 is predominately a product of T
cells.42,46,47 This suggests that T cells are most likely
responsible for driving IL33-mediated gastric pathology
through up-regulation of IL6 and IL9. In support of this, we
show that lymphocytes are crucial in IL33-mediated gastric
pathology as shown by the absence of gastric pathology in
lymphocyte-deﬁcient Rag1-/- mice. Interestingly, the number
of lymphocytes was not altered in the spleen and stomach of
IL33-treated mice despite the predominant effects of IL33 on
the spleen and stomach appearing to be Th2-immune driven
and their necessity for gastric pathology.Here, we show that IL33 is a stomach alarmin, which is
induced acutely during chemical damage or infection, but is
suppressed by chronic H pylori infection. Furthermore, we
show that the local gastric homeostatic factor TFF2 posi-
tively regulates IL33 expression in the stomach because
TFF2 null mice have substantially reduced IL33 expression.
This loss of IL33 may be a pivotal event in skewing the
immune response in chronic H pylori–induced gastric
pathologic progression. Furthermore, we show the ability of
IL33 to potently activate ILC2s and T cells in the gastric
mucosa, highlighting its ability to initiate an effective Th2
immune response. Although an acute Th2 response may be
beneﬁcial by preventing unchecked Th1/Th17 inﬂamma-
tion, we have shown that chronic Th2 activation produces
M2 macrophage polarization and increased STAT3 activa-
tion, both of which cause gastropathy,20,48,49 being partic-
ularly marked in the gastric cardia.References
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Supplementary Table 1.Fluorochromes Used for Identiﬁcation of Immune Cells by Flow Cytometry
Marker Fluorochromes Company Reference no.
CD4 V450 BD Biosciencesa 560468
CD8a APC-Cy7 BD Biosciencesa 561967
CD11b PE BD Biosciencesa 557397
CD11c APC BD Biosciencesa 550261
CD45R/B220 FITC BD Biosciencesa 553087
Ly-6G and Ly6C (Gr-1) PerCP-Cy5.5 BD Biosciencesa 552093
Immune cell Fluorochromes
Th CD4þ V450þ/APC-Cy7-
CTL CD8þ V450-/APC-Cy7þ
CD45R/B220þ B cells CD8a-/CD45R/B220þ
CD11bþLy6C/Gnet-low macrophages CD11bþ/Ly-6G and Ly6C (Gr-1)
CD11bþLy6C/Gþhigh neutrophils CD11bþ/Ly-6G and Ly6C (Gr-1)
CD11cþ DCs CD4þ/CD11cþ, CD8aþ/CD11cþ-, CD4-/ CD8a-/CD11cþ
aBD Biosciences, San Diego, CA.
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Supplementary Table 2.Primer Sequences Used for mRNA Expression Analyses via QRT-PCR
Gene Forward Reverse
IL33 GGTGTGGATGGGAAGAAGCTG GAGGACTTTTTGTGAAGGACG
ST2 CACCAGATCATTCACAGTTG CCACTTCCATTGTGTGGTTGTA
IL1a AACCCATGATCTGGAAGAGACC TGGTGCTGAGATAGTGTTTGTCC
IL1b CAGGCAGTATCACTCATTGTGG GTGCAGTTGTCTAATGGGAACG
IL4 GTCATCCTGCTCTTCTTTCTCG TCACTCTCTGTGGTTCTTCG
IL5 TTGACAAGCAATGAGACGATGAG GCCCCTGAAAGATTTCTCCAA
IL6 ACAAAGCCAGAGTCCTTCAGAGA CTGTTAGGAGAGCATTGGAAATTG
IL9 CGTCCCAACTGATGATTGTACC TGCATCTCTGTCTTCTGGAACG
IL11 CTGCAAGCCCGACTGGAA AGGCCAGGCGAGACATCA
IL12 TCTAGATGCTGGCCAGTACACC CCAAATGTGCTTGTCACCAC
IL13 GTGCCAAGATCTGTGTCTCTCC TTACAGAGGCCATGCAATATCC
IL17A TCTGTGTCTCTGATGCTGTTGC ACATTCTGGAGGAAGTCCTTGG
IL22 TCGTCAACCGCACCTTTATG GCCGGACATCTGTGTTGTTATC
IL23 GAGCAACTTCACACCTCCCTACTAG GGCCTGGAGGCTTCGAA
TNF-a TATGTCTCAGCCTCTTCTCATTCC ATGATCTGAGTGTGAGGGTCTGG
IFN-g TCAAGTGGCATAGATGTGGAAGAA TGGCTCTGCAGGATTTTCATG
TGF-b AATACAGGGCTTTCGATTCAGC TAGTTGGTATCCAGGGCTCTCC
iNOS CCCTCCAGTGTCTGGGAGCA TGCTTGTCACCACCAGCAGT
Ym1 TCTGGTGAAGGAAATGCGTAAA GCAGCCTTGGAATGTCTTTCTC
Ym2 TGCCCCGTTCAGTTCCAT TTGACGAAGGAATCTGATAACTGACT
Fizz1 CCTGCTGGGATGACTGCTACT CTCCACTCTGGATCTCCCAAGAT
RORgt GAGTTTGCCAAGCGGCTTT TCCATTGCTCCTGCTTTCAGT
RORa GCGGTTGACCTCGGCATAT ACGCTGGACTCTGCTGTTACC
GATA3 CGAGACATAGAGAGCTACGCAATC ACCTGAGTAGCAAGGAGCGTAGA
Amphiregulin CTATCTTTGTCTGCCATCATC CAACTTTTACCCTTGCAATTGCC
H2-Aa CCAGGGCCTTTATGAGTCACA GTCACCCAGCACACCACTTCT
H2-Ab1 GGAGACTCCGAAAGGCATTTC TGCGTCCCGTTGGTGAA
H2-Ea GCGGAGTTCTATCTTTTACCAGACA CTCATCGCCGTCAAAGTCAA
H2-Eb1 TGTGTGGCAGCTGTGATCCT AAACCATGGTCTGGAGTCTCTGA
SOCS3 AATACCTTTGACAAGCGGAC TGCTACTGCCTCTTCACAAC
Chymase TCTTACTCTTCATCTGCTGCTCCTT CCTCCAATGATCTCTCCAGCTT
Tryptase TGTGTGGGACCGGATGTTG TGGTCATGGTAATAGAGGTACTGCTT
IFN, interferon; iNOS, inducible nitric oxide synthase; SOCS3, suppressor of cytokine signaling 3; TGF, transforming growth
factor; TNF, tumor necrosis factor.
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Supplementary Table 3.Antibodies Used for Immunoblotting, Immunohistochemistry, and Immunoﬂuorescence
Speciﬁcity Antibody Manufacturer Reference no.
IL33 IL33 antibody R&D Systemsa AF3626
b-actin b-actin (13E5) Cell Signalingb 4970
Stat3 STAT3 Cell Signalingb 9132
p-stat3 Phospho-STAT3 (Tyr705) Cell Signalingb 9131
ERK1/2 P44/42 mitogen-activated protein kinase Cell Signalingb 9102
p-ERK1/2 Phospho-p44/42 mitogen-activated protein kinase (Thr202/Tyr204) Cell Signalingb 4377
H/K ATPase-b b subunit of H/K ATPase (Dr Ian VanDriel) Bio21 Institutec -
Ki-67 Ki-67 proliferation marker Abcamd Ab15580
Chymase mast cell chymase Abcamd Ab111239
UEA1 Ulex europaeus Sigmae L8262
Muc5AC Mucin 5AC Abcamd Ab3649
Ki-67 Ki-67 proliferation marker Thermo Scientiﬁcf RM-9106-SO
Intrinsic factor Intrinsic factor (Dr David Alpers) - -
ATPase, adenosine triphosphatase.
aR&D Systems, Minneapolis, MN.
bCell Signaling, Danvers, MA.
cBio21 Institute, Parkville, Australia.
dAbcam, Cambridge, MA.
eSigma, Cream Ridge, MA.
fThermo Scientiﬁc, Waltham, MA.
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